# Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects

> **NCT01203384** · PHASE1 · COMPLETED · sponsor: **CERESPIR** · enrollment: 48 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** CHF5074 1x
- **DRUG:** CHF5074 2x
- **DRUG:** CHF5074 3x
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01203384
- **Lead sponsor:** CERESPIR
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2015-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01203384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01203384, "Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01203384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*